FY2026 · ended Mar 31, 2026 · Revenue $0 · Filed Aug 14, 2026
Protagenic Therapeutics, Inc.\new (PTIX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2026, which ended Mar 31, 2026, it reported revenue of $0 and net income of $1.4 million. Free cash flow was -$2.8 million.
Revenue
$0
Net income
$1.37M
+124.8% vs prior year
Operating cash flow
$-2.81M
+33.4% vs prior year
Free cash flow
$-2.81M
+27.1% vs prior year
EPS
$0.59
+152.2% vs prior year
Dividend per share
None
Shares outstanding
1.81M
-75.9% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PTIX (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1022899
- Former names
- Atrinsic, Inc. (until Jun 20, 2016); NEW MOTION, INC. (until Jun 30, 2009); MPLC, Inc. (until Apr 2, 2007); MILLBROOK PRESS INC (until May 23, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Mar 31, 2026 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$4.5M | -$5.7M | -$4.5M | -$3.6M | -$4.1M |
| Net income | $1.4M | -$5.5M | -$5.0M | -$3.6M | -$4.5M |
| Diluted EPS | $0.59 | -$1.13 | -$1.15 | — | — |
| Operating cash flow | -$2.8M | -$4.2M | -$3.7M | -$2.0M | -$2.8M |
| Free cash flow | -$2.8M | — | -$3.9M | -$2.0M | — |
| Total assets | $3.7M | $2.0M | $4.3M | $8.0M | $11.1M |
| Total liabilities | $1.0M | $942,759 | $655,252 | $1.1M | $1.1M |
| Stockholders' equity | $2.6M | $1.0M | $3.7M | $6.9M | $9.9M |
| Cash and investments | $1.5M | $1.8M | $4.1M | $8.0M | $10.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 20, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Aug 19, 2026 | Jun 30, 2026 |
| 10-K | Annual report | Aug 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 7, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Mar 9, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 3, 2026 | Feb 3, 2026 |
All 705 Protagenic Therapeutics, Inc.\new SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.